News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Illumina, Inc. Announces Scale-Up of Genome Analyzers at The Broad Institute
November 5, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced that the Broad Institute has purchased 30 additional Genome Analyzers, increasing its total installed base of Illumina systems to 89.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Illumina, Inc.
MORE ON THIS TOPIC
Autoimmune disease
Amgen Ends Autoimmune Alliance With Kyowa Kirin Amid Safety, Efficacy Questions
February 2, 2026
·
2 min read
·
Tristan Manalac
Layoff Tracker
IO, Bitterroot Cut Staff Amid Strategic Efforts
February 2, 2026
·
48 min read
·
BioSpace Editorial Staff
Drug Pricing
Opinion: Pricing Transparency Is Coming to the Pharma Industry
February 2, 2026
·
5 min read
·
Joshua R. Mansbach
Insights
Biotech’s Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026
January 29, 2026
·
3 min read
·
Jennifer Smith-Parker
